Analysts See $-0.94 EPS for Spark Therapeutics, Inc. (ONCE)

October 13, 2018 - By Hazel Jackson

Spark Therapeutics, Inc. (NASDAQ:ONCE) LogoInvestors sentiment is 1.19 in 2018 Q2. Its the same as in 2018Q1. It is the same, as 17 investors sold Spark Therapeutics, Inc. shares while 46 reduced holdings. only 24 funds opened positions while 51 raised stakes. 37.08 million shares or 0.93% more from 36.74 million shares in 2018Q1 were reported.
Bnp Paribas Arbitrage Sa holds 2,242 shares or 0% of its portfolio. Amg National Bancorp accumulated 5,000 shares. Massachusetts-based Putnam has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Glenmede Na reported 12,714 shares. Finance Architects Inc has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 170 shares. Bankshares Of Montreal Can reported 284 shares stake. Cap Fund Mngmt invested in 15,379 shares. Bailard Inc accumulated 37,000 shares. Credit Agricole S A reported 9,830 shares. Clearbridge Invests Lc has 659,246 shares. Cwm Llc has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 120 shares. Proshare Advsr Lc has invested 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Bank Of Mellon stated it has 141,367 shares. Bokf Na reported 15,911 shares stake. Sector Gamma As invested in 0.43% or 31,600 shares.

Analysts expect Spark Therapeutics, Inc. (NASDAQ:ONCE) to report $-0.94 EPS on November, 6.They anticipate $0.96 EPS change or 50.53 % from last quarter’s $-1.9 EPS. After having $2.07 EPS previously, Spark Therapeutics, Inc.’s analysts see -145.41 % EPS growth. The stock increased 2.46% or $1.15 during the last trading session, reaching $47.94. About 378,961 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has declined 28.27% since October 14, 2017 and is downtrending. It has underperformed by 43.89% the S&P500.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage

Among 14 analysts covering Spark Therapeutics (NASDAQ:ONCE), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Spark Therapeutics had 20 analyst reports since April 19, 2018 according to SRatingsIntel. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, August 8 report. Mizuho maintained it with “Buy” rating and $9100 target in Tuesday, May 1 report. The rating was maintained by BMO Capital Markets with “Outperform” on Wednesday, May 9. The rating was maintained by Stifel Nicolaus on Wednesday, May 9 with “Buy”. On Wednesday, August 8 the stock rating was maintained by Stifel Nicolaus with “Buy”. RBC Capital Markets downgraded the shares of ONCE in report on Thursday, July 19 to “Sector Perform” rating. Cantor Fitzgerald maintained it with “Buy” rating and $10300 target in Monday, April 30 report. BMO Capital Markets downgraded the shares of ONCE in report on Wednesday, August 8 to “Market Perform” rating. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Buy” rating given on Tuesday, May 8 by Cantor Fitzgerald. Credit Suisse downgraded the shares of ONCE in report on Tuesday, August 7 to “Underperform” rating.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $1.80 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

More important recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were published by: Nasdaq.com which released: “Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate” on October 08, 2018, also Seekingalpha.com published article titled: “Regenxbio (Part IV): Elucidating The Prospects Of The AMD Franchise”, Bizjournals.com published: “Spark Therapeutics to add up to 500 jobs in West Philadelphia expansion” on October 11, 2018. More interesting news about Spark Therapeutics, Inc. (NASDAQ:ONCE) was released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” with publication date: October 10, 2018.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>